ArticleThe New England journal of medicine2013
Ibrutinib in relapsed chronic lymphocytic leukemia.
Article in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Haematologica · 2015Trial
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The New England journal of medicine · 2014Trial
- Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.Research and practice in thrombosis and haemostasis · 2026Article
- Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges.Frontiers in pharmacology · 2024Review
- Review
- Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.Blood advances · 2019Article
- Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.Haematologica · 2019Article
- Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.Platelets · 2019Article
- Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.Haematologica · 2018Article
- Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.Nature genetics · 2018Article
- Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.British journal of pharmacology · 2018Article
- The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.Expert review of clinical immunology · 2016Review
- Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.Haematologica · 2016Article
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.Haematologica · 2015Review
- Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Scientific reports · 2015Article
- Article
- Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Cancer immunology research · 2015Article
- Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.Oncotarget · 2014Article
- Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.Oncotarget · 2014Article
- B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292.ImmunoTargets and therapy · 2014Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24066760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.